[Drug therapy of chronic arterial occlusive diseases of the lower extremities with butalamine-HCl].
In a multicentre study a total of 113 patients suffering from disturbed blood flow conditions of the lower extremities (type II Fontaine) were treated with butalamine hydrochloride tablets, each containing 80 mg of the active principle. In 96% of the cases given a daily dose of 3 x 2 tablets and in 82% of those treated with a daily dose of 3 x 1 tablet both subjective and objective clinical symptoms, such as walking distance and Ratschow's testing parameters, were found to be improved. In view of the findings that metabolic functions as well as systemic blood flow conditions were not affected and that the drug was furthermore well tolerated by the gastrointestinal system, butalamine hydrochloride proved to be an effective therapeutic in long-term treatment of patients suffering from blood flow disorders of the lower extremities.
D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007866:Leg / Q000098:blood supply*; D008297:Male; D010069:Oxadiazoles / Q000008:administration & dosage / Q000627:therapeutic use*
D010069:Oxadiazoles
Pharmakotherapie chronisch arterieller Verschlusskrankheiten der unteren Extremitäten mit Butalamin-HCl.